Working together for people with psoriasis

At UCB, we want to play our part in making a lasting difference in the lives of psoriasis (PSO) and psoriatic arthritis (PSA) patients. Our experience in healthcare has taught us that we can maximise our impact by working with others who share our goals.

That is why we are pleased to have joined the Partner Program of the International Federation of Psoriasis Associations (IFPA). IFPA is a pivotal international patient advocacy organization working exclusively in PSO and PSA.

The organization seeks to raise awareness about these diseases and improve living conditions for all psoriasis patients worldwide. They do this in several ways, including by improving access to early and accurate diagnosis for PSO patients, and by making PSO patient care a priority for national health systems and globally.

As a recognized partner with IFPA, UCB is now empowered to support this organization and to partner on mutually beneficial projects. This strategic partnership will allow UCB to bring real world value to psoriasis patients. We will do this by supporting international, regional and local patient associations to better understand the unique needs of psoriasis patients, particularly women, and to drive advocacy and patient support policies.

IFPA has made psoriasis a global health priority by supporting the adoption of the World Health Organization’s (WHO) Resolution on Psoriasis in 2014, followed by the WHO Global Report on Psoriasis in 2016. These set a clear accountability framework for improving PSO patient care.

This year UCB attended the 5th World Psoriasis & Psoriatic Arthritis Conference 2018, organized by IFPA, and sponsored clinical psoriasis research, as well as research on the impact of psoriasis on patients, and how to optimize disease management.

We recognize the excellent work the Federation has done and look forward to lending our support to their cause.